Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Metadata lists "Phio Pharmaceuticals Corp.", but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report).
Date of Report: May 12, 2016.
Reporting Period: Quarter ended March 31, 2016.
Event: Announcement of results of operations and financial condition for the quarter ended March 31, 2016.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for the actual results.
- Revenue: Not provided in the filing text.
- Profit/Loss: Not provided in the filing text.
- Cash Flow: Not provided in the filing text.
- Margins: Not provided in the filing text.
- Debt and Liquidity: Not provided in the filing text.
Material Changes
The filing text does not provide specific numerical comparisons or material changes versus the prior comparable period. It only confirms that results for the quarter ended March 31, 2016, were reported.
Guidance, Outlook, and Risks
Management Commentary: The filing states that results were reported via a press release attached as Exhibit 99.1. No specific commentary, guidance, or outlook is included in the text of the Form 8-K itself.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name (RXi Pharmaceuticals Corporation vs. Phio Pharmaceuticals Corp. in metadata).
- Review Exhibit 99.1 (Press Release dated May 12, 2016) for actual revenue, net loss, and cash position figures.
- Confirm the specific details of the "Results of Operations" referenced but not detailed in this summary.
- Check for any subsequent filings that may incorporate the press release by reference.